Agilent to Acquire Biocare Medical, a Global Leader in Clinical and Research Pathology Solutions
📰 Agilent Technologies has entered a definitive agreement to acquire Biocare Medical for $950 million in an all-cash transaction.
🧬 Biocare is being valued as a global leader in clinical and research pathology, specifically known for its antibody portfolio and R&D capabilities.
💰 The target company generated over $90 million in revenue in 2025 and has posted annual double-digit growth in revenue and profit since 2021.
🤝 The acquisition is led by investor groups Excellere Partners and GHO Capital Partners LLP, who will sell the business to Agilent.
💼 Biocare CEO Luis de Luzuriaga stated that joining Agilent allows for expanded operational scale and better service for patients served in oncology.
📈 Agilent President Padraig McDonnell noted the deal enhances their pathology portfolio and reflects a strategy of disciplined capital allocation.
🎯 Strategic benefits include expanding Agilent's immunohistochemistry offering through Biocare's complementary antibody, reagent, and instrument portfolios.
🌍 Combining Agilent's global operations with Biocare's strong U.S. commercial presence will create a platform to serve more research and clinical customers.
💵 The transaction is expected to be accretive to Agilent's top-line growth rate and margin profile in the first year following close.
⏱️ Agilent expects earnings per share (EPS) accretion approximately 12 months after the deal closes.
📅 The acquisition is subject to regulatory approvals and is expected to close by no later than Agilent's fourth fiscal quarter of 2026.
🏢 Upon closing, Biocare will become part of Agilent's Life Sciences and Diagnostics Markets Group.
⚖️ Barclays serves as financial adviser for Agilent, while Jefferies acts as the exclusive financial adviser for Biocare in this deal.
🔬 Biocare specializes in solutions including immunohistochemistry (IHC), in situ hybridization (ISH), and fluorescence in situ hybridization (FISH).
- Agilent announced a definitive agreement to acquire Biocare Medical for $950 million in an all-cash transaction, reflecting strong market confidence.
- Biocare Medical has achieved annual double-digit revenue and profit growth since 2021 and generated over $90 million in revenue in 2025.
- The acquisition is expected to be accretive to Agilent's top-line growth rate and margin profile starting in the first year following closing.
- EPS accretion is projected to begin approximately 12 months following the transaction close, signaling strong long-term financial value creation.
- Biocare's portfolio of more than 300 specialized antibodies demonstrates proven R&D capability and innovation strength.
- Combining Agilent's global reach with Biocare's strong U.S. commercial presence will unlock greater market access for customers.
- The transaction is expected to close by no later than Agilent's fourth fiscal quarter of 2026, providing certainty in execution timeline.
- Biocare has been recognized as a global leader in clinical and research pathology solutions, improving diagnosis and treatment outcomes.
- The acquisition by Agilent adds $950 million in all-cash consideration to the company's capital expenditure plan, which may increase short-term free cash flow pressure before integration synergies materialize.
- Regulatory approvals are required as a customary closing condition for the transaction, introducing potential delays or uncertainty regarding the deal timeline and finalization.
- The integration of Biocare's portfolio into Agilent's existing Life Sciences and Diagnostics Markets Group carries execution risk, as combining commercial operations may disrupt current revenue streams initially.
- Agilent expects EPS accretion only approximately 12 months following close, suggesting a one-year period where the deal could dilute earnings rather than enhance them.
